US FDA gives approval to sBLA for expanded use of Takeda’s TAKHZYRO
TAKHZYRO is a completely human monoclonal antibody that particularly binds and reduces plasma kallikrein activity. Before this approval, the only approved routine prophylaxis treatment options for children